EverSource Wealth Advisors’s MaxCyte MXCT Stock Holding History

EverSource Wealth Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.83K	Buy	3,116 +1,721	+123%	+$1.72K	﹤0.01%	3419
2026 Q1	$980	Buy	1,395 +619	+80%	+$578	﹤0.01%	3861
2025 Q4	$1.2K	Sell	776 -243	-24%	-$388	﹤0.01%	3662
2025 Q3	$1.61K	Buy	1,019 +205	+25%	+$356	﹤0.01%	3582
2025 Q2	$1.77K	Buy	814 +339	+71%	+$821	﹤0.01%	3544
2025 Q1	$1.3K	Buy	475 +361	+317%	+$1.42K	﹤0.01%	3127
2024 Q4	$474	Buy	+114	New	+$431	﹤0.01%	3218
2022 Q1	–	Sell	-243	Closed	-$2K	–	1797
2021 Q4	$2K	Buy	+243	New	+$2.61K	﹤0.01%	1582

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

EverSource Wealth Advisors's MXCT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its MaxCyte (MXCT) stake by 123% in Q2 2026, buying an estimated $1.72K and bringing the position to 3,116 shares worth $3.83K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

EverSource Wealth Advisors first reported a position in MXCT in Q4 2021 and has held it in 8 quarters since. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

EverSource Wealth Advisors held 3,116 shares of MaxCyte worth $3.83K as of Q2 2026.
EverSource Wealth Advisors bought 1,721 MaxCyte shares in Q2 2026, an estimated $1.72K.
MaxCyte made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3419 holding.
EverSource Wealth Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 8 quarters since.
122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.